Rule 2.7, 3.10.3, 3.10.4, 3.10.5

Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

Praei	mium Limited	
ABN 74 09	98 405 826	
We (the entity) give ASX the following	g information.
	t 1 - All issues nust complete the relevant sections (attac	h sheets if there is not enough space).
1	*Class of *securities issued or to be issued	Ordinary Shares
2	Number of *securities issued or to be issued (if known) or maximum number which may be issued	461,078
3	Principal terms of the *securities (eg, if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	Shares issued pursuant to the Praemium Directors & Employee Benefits Plan in recognition of the performance of a staff member and in lieu of cash directors fees to non executive directors of the UK subsidiary group.

Name of entity

⁺ See chapter 19 for defined terms.

4 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment

5 Issue price or consideration

As to 150,000 - nil.

Yes.

As to 311,078 Shares – 20 cents per share.

6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets) As to 150,000 – bonus payment to reward staff.

As to 311,078 Shares – in lieu of cash payment for services as non executive directors of subsidiary.

7 Dates of entering *securities into uncertificated holdings or despatch of certificates

6 – 7 January 2011

8 Number and +class of all +securities quoted on ASX (*including* the securities in clause 2 if applicable)

Number	⁺ Class
229,031,744	228,570,666 existing fully paid ordinary shares plus 461,078 new fully paid ordinary shares issued as set out above

Appendix 3B Page 2 24/10/2005

⁺ See chapter 19 for defined terms.

9 Number and *class of all *securities not quoted on ASX (including the securities in clause 2 if applicable)

Number	+Class				
8,333,952	4,723,953 Options				
	and Performance				
	Rights plus				
	3,609,999				
	Performance Rights				
	(structured as EMI				
	Options under UK				
	law) issued to as				
	incentives to key				
	management and				
	operational staff in				
	the UK) as set out in				
	attachment A				

Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

No change in dividend policy

Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?
12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities will be offered
14	⁺ Class of ⁺ securities to which the offer relates
15	⁺ Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions

1/1/2003 Appendix 3B Page 3

⁺ See chapter 19 for defined terms.

Appendix 3B New issue announcement

	r	
18	Names of countries in which the entity has *security holders who will not be sent new issue documents	
	Note: Security holders must be told how their entitlements are to be dealt with.	
	Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	
20	Names of any underwriters	
	L	
21	Amount of any underwriting fee or commission	
22	Names of any brokers to the	
22	issue	
22	Fee or commission payable to the	
23	broker to the issue	
24	Amount of any handling fee payable to brokers who lodge	
	acceptances or renunciations on behalf of *security holders	
	TC .1	
25	If the issue is contingent on +security holders' approval, the date of the meeting	
	_	
26	Date entitlement and acceptance form and prospectus or Product	
	Disclosure Statement will be sent to persons entitled	
	10.1	
27	If the entity has issued options, and the terms entitle option	
	holders to participate on exercise, the date on which	
	notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
20	Date rights trading will and (:f)	
29	Date rights trading will end (if applicable)	

Appendix 3B Page 4 1/1/2003

⁺ See chapter 19 for defined terms.

30	How do *security holders sell their entitlements in full through a broker?
31	How do *security holders sell part of their entitlements through a broker and accept for the balance?
32	How do *security holders dispose of their entitlements (except by sale through a broker)?
33	⁺ Despatch date
	3 - Quotation of securities ed only complete this section if you are applying for quotation of securities
34	Type of securities (tick one)
(a)	Securities described in Part 1
(b)	All other securities Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entitio	es that have ticked box 34(a)
Addit	ional securities forming a new class of securities
Tick to docume	indicate you are providing the information or ents
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
36	If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000

+ See chapter 19 for defined terms.

1/1/2003 Appendix 3B Page 5

Appendix 3B New issue announcement

	100,001 and over
37	A copy of any trust deed for the additional *securities

Appendix 3B Page 6 1/1/2003

⁺ See chapter 19 for defined terms.

Entitie	es that have ticked box 34(b)		
38	Number of securities for which [†] quotation is sought		
39	Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: • the date from which they do • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period (if issued upon conversion of another security, clearly identify that other security)		
42	Number and *class of all *securities quoted on ASX (including the securities in clause 38)	Number	⁺ Class

1/1/2003 Appendix 3B Page 7

⁺ See chapter 19 for defined terms.

Quotation agreement

- [†]Quotation of our additional [†]securities is in ASX's absolute discretion. ASX may quote the [†]securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the *securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the *securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the *securities to be quoted under section 1019B of the Corporations Act at the time that we request that the *securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before †quotation of the †securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

(Director/Company secretary)

Cathring Nole

Date: 7 January 2011

Appendix 3B Page 8 1/1/2003

⁺ See chapter 19 for defined terms.

SP Code	Discription	Issue Date	Expiry Date	Issue Price	No on register 20/12/10 (date of last 38)	Expired / Cancelled / Lapsed / failure to vest	Vested/ Exercised	Allocations	No on Register of 7 January 2011 (Date of this 38)
SOSAUS	Options - exercisable for \$0.30c expiring 30								
	December 2010	31/12/2008	31/12/2010	\$0.300	716,667				716,667
SOSAUS	Options – exercisable for \$0.35c expiring 30 December 2011	31/12/2008	31/12/2011	\$0.350	62,286				62,286
SOSAUS	Options – exercisable for \$0.155 expiring 30 September 2011	15/03/2010	30/09/2011	\$0.155	870,000				870,000
SOSUK	Options – exercisable for \$0.165 expiring 30 September 2011	31/12/2009	30/09/2011	\$0.165	440.000				440.000
PSUOPT	Options – exercisable for \$1.67 expiring 07 August 2011	13/03/2008	7/08/2011	\$1.670	135,000				135,000
					2.223.953	_			2.223.95
	Performance Rights - nil exercise price Tranch 2 - expire/vest 30/10/11	30/10/2010	30/10/2011	nil	975,000				975,000
	Performance Rights - nil exercise price Tranch 3 - expire/vest 30/10/12	30/10/2010	30/10/2011	nil	975,000				975,00
	Performance Rights - nil exercise price Tranch 5 - expire/vest 30/10/11	29/10/2010	30/10/2011	nil	50,000				50,00
	Performance Rights - nil exercise price Tranch 6 - expire/vest 30/10/11	1/06/2010	30/10/2011	nil	50,000				50,00
	Performance Rights - nil exercise price Tranch 7 - expire/vest 30/10/11	29/10/2010	30/10/2011	nil	100,000				100,00
	Performance Rights - nil exercise price Tranch 8 - expire/vest 30/10/12	29/10/2010	30/10/2012	nil	100,000				100,00
	Performance Rights - nil exercise price Tranch 7 - expire/vest 30/10/11	14/12/2010	30/10/2011	nil	125,000				125,00
	Performance Rights - nil exercise price Tranch 8 - expire/vest 30/10/12	14/12/2010	30/10/2012	nil	125,000				125,00
	Performance rights (EMI Options (UK)) - nil exercise price Tranch 9 - Earliest Vest Date (subject to satisfaction of performance conditions) 6/4/10	23/12/2010	1/12/2020	nil				1,336,668	1.336.66
	Performance rights (EMI Options (UK)) - nil exercise price Tranch 10 - Earliest Vest Date (subject to satisfaction of performance conditions) 30/10/11	23/12/2010	1/12/2020	nil				1,136,667	
	Performance rights (EMI Options (UK)) - nil exercise price Tranch 11 - Earliest Vest Date (subject to satisfaction of performance								
	conditions) 30/10/11	23/12/2010	1/12/2020	nil				1,136,664	1,136,66
					2,500,000	-		3,609,999	6,109,99
					4.723.953				8.333.95

⁺ See chapter 19 for defined terms.